Page 168 - NobleCon19revC2_Neat

Health Care
Date November 21, 2023 Health Care
52wk High $9.81
52wk Low $0.43 Tonix Pharmaceuticals Hold TNXP $0.49
26 Main Street
Chatham, NJ 07928

(USD - in millions) www.tonixpharma.com
Market Cap 11.5
Enterprise 5.7
Basic Shares Out. 23.85 COMPANY OVERVIEW
Float 21.15
Institutional Holdings 4.31% Detailed Analysis:Channelchek.com
Short Interest 0.33 Tonix is a clinical-stage biopharmaceutical company focused on
Avg. 90-Day Volume 0.30 discovering, licensing, acquiring and developing therapeutics to treat
and prevent human disease and alleviate suffering. Tonix’s portfolio is
composed of central nervous system (CNS), rare disease, immunology
and infectious disease product candidates. Tonix’s CNS portfolio
EPS Data includes both small molecules and biologics to treat pain, neurologic,
psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-
2021 2022 2023 102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3
CQ1 (14.00) (10.00) (3.25) development for the management of fibromyalgia with a new Phase 3
CQ2 (14.00) (7.63) (2.68) study launched in the second quarter of 2022 and interim data
expected in the second quarter of 2023. TNX-102 SL is also being
CQ3 (10.00) (4.31) (1.83) developed to treat Long COVID, a chronic post-acute COVID-19
CQ4 (14.00) (3.50) (1.33) condition.
CY (52.00) (20.44) (7.81) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 6.80
ROE (ttm) -69.20
Debt-to-Total Cap. (mrq) 0.94
Fiscal Year End 31-Dec
26 Main StreetChatham NJ 07928

Key Executives
CEO: Lederman, Seth
CFO: Saenger, Bradley
COO: Morris, Jessica
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures